Catabasis Pursues Bifunctional Mutation-Agnostic Approach To DMD
Executive Summary
Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified a NF-κB inhibitor – edasalonexent – as a potential Duchenne muscular dystrophy (DMD) treatment. Speaking at the 2017 Biotech Showcase, Dr Jill Milne, co-founder, president and CEO of Catabasis, describes the company’s ambitions to pursue a pivotal Phase III trial this year.